FORTREA UNVEILS HOLISTIC APPROACH TO ENHANCE DIVERSITY & INCLUSIVITY IN CLINICAL RESEARCH

DURHAM, N.C., May 31 (Bernama) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced its comprehensive and integrated solution to improve the diversity and inclusion (D&I) of participants in clinical trials. Fortrea’s D&I solution is designed to expand patient access to participate in clinical trials and address the U.S. Food and Drug Administration (FDA) requirements, under The Food and Drug Omnibus Reform Act, to increase enrollment of underrepresented populations in clinical trials.

For full release, click here : http://mrem.bernama.com/viewsm.php?idm=48713